Both medicines are given as a subcutaneous injection, which means an injection under the skin, once a week. People in the study receive one of several dose plans of NNC0487-0111 or semaglutide, and some study groups receive placebo. The study follows changes in body weight, blood sugar, waist size, blood pressure, and other health measures over time. It also looks at side effects, including low blood sugar, which can happen when blood sugar drops too far.

The study is planned to run for a long period, with treatment and follow-up visits spread across the study time. The medicines are given in a pre-filled pen, and the course of the study is designed to compare how the different treatments work and how safe they are in adults with excess body weight and type 2 diabetes.

People in the study receive one of several weekly dose levels of NNC0487-0111 or placebo. The treatment is given with a pre-filled pen and the study lasts for many months. During the study, body weight, blood sugar control, and other health changes are followed, along with any unwanted effects.

The study is designed to find out whether NNC0487-0111 can help reduce body weight in people who have excess body weight and type 2 diabetes. It also looks at changes in waist size, blood sugar, blood pressure, blood fats, and quality of life, as well as safety issues such as low blood sugar and other side effects.

Participants in the study will receive either the test medication NNC0662-0419, a comparator drug named Ozempic, or a placebo. The study will monitor changes in HbA1c, which is a blood test that shows the average blood sugar levels over the past few months. Additionally, changes in body weight will be observed during the course of the research.

During the study, participants will receive either cagrilintide at different dose levels or placebo for a treatment period of up to 64 weeks. All participants will also receive guidance on lifestyle changes to support weight management. The study will measure changes in body weight and track how many people achieve weight loss of at least 5%, 10%, or 15% of their starting weight. Other measurements will include changes in waist size, blood sugar control measured by HbA1c (a test that shows average blood sugar levels over time), blood pressure, and various blood fats such as cholesterol and triglycerides.

The study will also assess quality of life using questionnaires that ask about physical function and overall well-being, and will monitor any side effects or health problems that occur during treatment. Safety will be carefully tracked, including any episodes of low blood sugar, which can happen when blood sugar drops below normal levels. Participants may continue taking their usual diabetes medications during the study if they have been on a stable dose for a certain period before joining.

The purpose of this study is to find out if ziltivekimab works better than placebo in reducing the risk of death from heart and blood vessel problems and preventing heart failure events such as hospital stays or urgent visits for worsening heart failure. The study will also look at other health outcomes including the combined risk of death from heart problems, heart attacks, and strokes, as well as how the treatment affects kidney function, quality of life, and inflammation levels in the body. Quality of life will be measured using questionnaires that ask about symptoms and daily activities.

During the study, participants will receive monthly injections for up to 48 months. The study will track various health events including hospitalizations for heart failure, deaths, heart attacks, strokes, and changes in heart and kidney function. Blood tests will be done to measure inflammation markers like hs-CRP and heart stress markers like NT-proBNP. Heart function will be checked using echocardiography, which is an ultrasound test that creates pictures of the heart. The study will continue until enough information has been collected to determine whether ziltivekimab is effective in helping people with this type of heart failure and inflammation.

During the study, participants will receive either NNC0487-0111, placebo, or standard diabetes medications including metformin and a type of medication called SGLT2 inhibitor (dapagliflozin). The treatment period will last for 36 months, during which participants will need to wear a special device that continuously monitors their blood sugar levels.

The study will measure several health indicators, including changes in blood sugar control (HbA1c), body weight, blood pressure, and various blood tests. Researchers will also monitor kidney function and check for any side effects of the treatment. This research will help determine the most effective and safe dose of the new medication for future use in treating diabetes.

The purpose of the study is to evaluate how safe plozasiran is for long-term use in people with hypertriglyceridemia. Participants in the study will receive injections of plozasiran and will be monitored over time to see how their triglyceride levels change. The study will also look at other factors, such as changes in cholesterol levels and any side effects that may occur during the treatment period.

Throughout the study, participants will have regular check-ups to track their health and any changes in their condition. The study aims to provide valuable information on the safety and potential benefits of plozasiran for managing high triglyceride levels in the long term. This research could help improve treatment options for individuals with hypertriglyceridemia.

The purpose of the study is to evaluate how effective and safe two different doses of CHF6001 DPI are when added to the usual maintenance therapy for COPD. This maintenance therapy typically includes a combination of inhaled corticosteroids (ICS), long-acting beta-agonists (LABA), and long-acting muscarinic antagonists (LAMA). The study will last for 52 weeks, during which participants will be randomly assigned to different groups. Some will receive CHF6001 DPI along with their regular treatment, while others will receive Roflumilast or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving which treatment until the study is completed.

Throughout the study, participants will be monitored to see how the treatments affect their COPD symptoms, particularly the frequency and severity of flare-ups, also known as exacerbations. The study will also assess changes in lung function and quality of life. By the end of the study, researchers hope to determine whether adding CHF6001 DPI to the standard COPD treatment can help reduce the number of moderate and severe exacerbations in patients with COPD and chronic bronchitis.

The purpose of this study is to assess how effective and safe Plozasiran is in reducing fasting triglyceride levels in adults with severe hypertriglyceridemia. Participants in the study will receive either Plozasiran or a placebo, which is a substance with no active medication. The study will last for about 12 months, during which participants will receive regular injections and have their triglyceride levels monitored at various points to see how they change over time.

Throughout the study, participants will be closely monitored for any changes in their health and any side effects they might experience. The goal is to determine if Plozasiran can significantly lower triglyceride levels compared to the placebo, and to see if it helps more participants reach healthier triglyceride levels. This research could lead to a new treatment option for people with severe hypertriglyceridemia, potentially improving their health and reducing the risk of complications associated with high triglyceride levels.

Participants in the study will be randomly assigned to one of two treatment groups: one group will receive Milvexian and a matching placebo that looks like Apixaban, while the other group will receive Apixaban and a matching placebo that looks like Milvexian. This means that all participants take both an active medication and a placebo, allowing the study to be conducted in a double-blind manner, so that neither the participants nor the researchers know which active treatment is being administered.

The study will last for up to 48 weeks. During this period, participants will take their assigned medication orally. Some participants may also receive a solution for infusion, known as Ondexxya, to help manage any potential side effects.

The main goal is to monitor the time it takes for participants to experience a stroke or a non-CNS systemic embolism, which is a type of blood clot that occurs outside the brain and spinal cord. Secondary goals include observing the occurrence of major bleeding and other cardiovascular events. The study aims to provide valuable information on the safety and effectiveness of Milvexian compared to Apixaban, potentially offering a new treatment option for individuals with Atrial Fibrillation.

Participants in the study will receive either Obicetrapib or a placebo, which looks like the medication but does not contain the active ingredient. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure the results are unbiased. The study will last for a period of time, during which participants will take the medication or placebo and attend regular check-ups to monitor their health and any changes in their condition.

The goal of the study is to gather information on how Obicetrapib affects the risk of serious cardiovascular events in people with ASCVD. By participating, researchers hope to better understand the potential benefits of this medication for those who are not adequately helped by their current treatments. The study will provide valuable insights into the effectiveness of Obicetrapib in managing heart and blood vessel health in individuals with this condition.